These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36334078)

  • 1. Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage.
    Mancikova V; Pesova M; Pavlova S; Helma R; Zavacka K; Hejret V; Taus P; Hynst J; Plevova K; Malcikova J; Pospisilova S
    Mol Oncol; 2023 Jan; 17(1):82-97. PubMed ID: 36334078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.
    te Raa GD; Moerland PD; Leeksma AC; Derks IA; Yigittop H; Laddach N; Loden-van Straaten M; Navrkalova V; Trbusek M; Luijks DM; Zenz T; Skowronska A; Hoogendoorn M; Stankovic T; van Oers MH; Eldering E; Kater AP
    Cell Death Dis; 2015 Aug; 6(8):e1852. PubMed ID: 26247737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The p53 pathway induction is not primarily dependent on Ataxia Telangiectasia Mutated (ATM) gene activity after fludarabine treatment in chronic lymphocytic leukemia cells.
    Navrkalova V; Sebejova L; Zemanova J; Jaskova Z; Trbusek M
    Leuk Lymphoma; 2013 Aug; 54(8):1840-3. PubMed ID: 23808769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
    Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
    Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
    Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
    Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
    Stankovic T; Hubank M; Cronin D; Stewart GS; Fletcher D; Bignell CR; Alvi AJ; Austen B; Weston VJ; Fegan C; Byrd PJ; Moss PA; Taylor AM
    Blood; 2004 Jan; 103(1):291-300. PubMed ID: 12958068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of SF3B1 mutations in CLL on the DNA-damage response.
    Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
    Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
    Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
    Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
    Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
    Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
    Navrkalova V; Sebejova L; Zemanova J; Kminkova J; Kubesova B; Malcikova J; Mraz M; Smardova J; Pavlova S; Doubek M; Brychtova Y; Potesil D; Nemethova V; Mayer J; Pospisilova S; Trbusek M
    Haematologica; 2013 Jul; 98(7):1124-31. PubMed ID: 23585524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
    Cejkova S; Rocnova L; Potesil D; Smardova J; Novakova V; Chumchalova J; Zezulkova D; Borsky M; Doubek M; Brychtova Y; Pospisilova S; Klabusay M; Mayer J; Trbusek M
    Eur J Haematol; 2009 Feb; 82(2):133-42. PubMed ID: 19018867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Agathanggelou A; Smith E; Davies NJ; Kwok M; Zlatanou A; Oldreive CE; Mao J; Da Costa D; Yadollahi S; Perry T; Kearns P; Skowronska A; Yates E; Parry H; Hillmen P; Reverdy C; Delansorne R; Paneesha S; Pratt G; Moss P; Taylor AMR; Stewart GS; Stankovic T
    Blood; 2017 Jul; 130(2):156-166. PubMed ID: 28495793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
    Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
    Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
    Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
    Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
    Agathanggelou A; Weston VJ; Perry T; Davies NJ; Skowronska A; Payne DT; Fossey JS; Oldreive CE; Wei W; Pratt G; Parry H; Oscier D; Coles SJ; Hole PS; Darley RL; McMahon M; Hayes JD; Moss P; Stewart GS; Taylor AM; Stankovic T
    Haematologica; 2015 Aug; 100(8):1076-85. PubMed ID: 25840602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRIMA-1
    Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
    Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
    te Raa GD; Malcikova J; Pospisilova S; Trbusek M; Mraz M; Garff-Tavernier ML; Merle-Béral H; Lin K; Pettitt AR; Merkel O; Stankovic T; van Oers MH; Eldering E; Stilgenbauer S; Zenz T; Kater AP;
    Leuk Lymphoma; 2013 Aug; 54(8):1849-53. PubMed ID: 23614766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
    Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
    Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
    Alvi AJ; Austen B; Weston VJ; Fegan C; MacCallum D; Gianella-Borradori A; Lane DP; Hubank M; Powell JE; Wei W; Taylor AM; Moss PA; Stankovic T
    Blood; 2005 Jun; 105(11):4484-91. PubMed ID: 15692065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells.
    Lin K; Rockliffe N; Johnson GG; Sherrington PD; Pettitt AR
    Oncogene; 2008 Apr; 27(17):2445-55. PubMed ID: 17982489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.